Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (144)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Lane, D P
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lane, D P
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

British Medical Bulletin 50:582-599 (1994)
© 1994 The British Council

research-article

p53 and human cancers

D P Lane

Cancer Research Campaign Laboratories, Department of Biochemistry, University of Dundee Dundee, UK

Abstract

Mutations in the p53 gene are one of the commonest specific genetic changes found in human cancer. The p53 gene is not required for normal development but lack of p53 function confers an enormously elevated risk of developing cancer, thus it seems truly to act as a tumour suppressor gene. The p53 protein is normally present in minute amounts in cells but when cells are exposed to genotoxic stimuli p53 levels rise rapidly and initiate a programme of cell death, probably by means of transcriptional regulation. This response is lost in many tumour cells as they have either inactivated their p53 genes by mutation or blocked the activity of p53 through the production of proteins that bind to it and neutralise it. Mutant p53 proteins accumulate to high levels in many cancer cells and the p53 protein and the p53 response to DNA damage represent key points for therapeutic intervention.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Mol. Cell. Biol.Home page
M. J. Scian, K. E. R. Stagliano, M. A. E. Anderson, S. Hassan, M. Bowman, M. F. Miles, S. P. Deb, and S. Deb
Tumor-Derived p53 Mutants Induce NF-{kappa}B2 Gene Expression
Mol. Cell. Biol., November 15, 2005; 25(22): 10097 - 10110.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
H H Ishii, G C Gobe, J Yoneyama, M Mukaide, and Y Ebihara
Role of p53, apoptosis, and cell proliferation in early stage Epstein-Barr virus positive and negative gastric carcinomas
J. Clin. Pathol., December 1, 2004; 57(12): 1306 - 1311.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. J. Scian, K. E. R. Stagliano, M. A. Ellis, S. Hassan, M. Bowman, M. F. Miles, S. P. Deb, and S. Deb
Modulation of Gene Expression by Tumor-Derived p53 Mutants
Cancer Res., October 15, 2004; 64(20): 7447 - 7454.
[Abstract] [Full Text] [PDF]

Home page
 Occup. Environ. Med.Home page
J Shaham, Y Bomstein, R Gurvich, M Rashkovsky, and Z Kaufman
DNA-protein crosslinks and p53 protein expression in relation to occupational exposure to formaldehyde
Occup. Environ. Med., June 1, 2003; 60(6): 403 - 409.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
J M D Wheeler, B F Warren, N J McC Mortensen, H C Kim, S C Biddolph, G Elia, N E Beck, G T Williams, N A Shepherd, A C Bateman, et al.
An insight into the genetic pathway of adenocarcinoma of the small intestine
Gut, February 1, 2002; 50(2): 218 - 223.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
E. S. Schernhammer, F. Laden, F. E. Speizer, W. C. Willett, D. J. Hunter, I. Kawachi, and G. A. Colditz
Rotating Night Shifts and Risk of Breast Cancer in Women Participating in the Nurses' Health Study
J Natl Cancer Inst, October 17, 2001; 93(20): 1563 - 1568.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. R. Pettitt, P. D. Sherrington, G. Stewart, J. C. Cawley, A. M. R. Taylor, and T. Stankovic
p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation
Blood, August 1, 2001; 98(3): 814 - 822.
[Abstract] [Full Text] [PDF]

Home page
 J. Med. Genet.Home page
J M D Wheeler, A Loukola, L A Aaltonen, N J M. Mortensen, and W F Bodmer
The role of hypermethylation of the hMLH1 promoter region in HNPCC versus MSI+ sporadic colorectal cancers
J. Med. Genet., August 1, 2000; 37(8): 588 - 592.
[Abstract] [Full Text]

Home page
 GutHome page
J M D WHEELER, W F BODMER, and N J M. MORTENSEN
DNA mismatch repair genes and colorectal cancer
Gut, July 1, 2000; 47(1): 148 - 153.
[Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
A. Carnero, J. D. Hudson, G. J. Hannon, and D. H. Beach
Loss-of-function genetics in mammalian cells: the p53 tumor suppressor model
Nucleic Acids Res., June 1, 2000; 28(11): 2234 - 2241.
[Abstract] [Full Text] [PDF]

Home page
 Arch DermatolHome page
W. Boonchai, M. Walsh, M. Cummings, and G. Chenevix-Trench
Expression of p53 in Arsenic-Related and Sporadic Basal Cell Carcinoma
Arch Dermatol, February 1, 2000; 136(2): 195 - 198.
[Abstract] [Full Text] [PDF]

Home page
 ScienceHome page
D. W. Bell, J. M. Varley, T. E. Szydlo, D. H. Kang, D. C. Wahrer, K. E. Shannon, M. Lubratovich, S. J. Verselis, K. J. Isselbacher, J. F. Fraumeni, et al.
Heterozygous Germ Line hCHK2 Mutations in Li-Fraumeni Syndrome
Science, December 24, 1999; 286(5449): 2528 - 2531.
[Abstract] [Full Text]

Home page
 J. Biol. Chem.Home page
M. Tan, S. Li, M. Swaroop, K. Guan, L. W. Oberley, and Y. Sun
Transcriptional Activation of the Human Glutathione Peroxidase Promoter by p53
J. Biol. Chem., April 23, 1999; 274(17): 12061 - 12066.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
U. Kressner, M. Inganas, S. Byding, I. Blikstad, L. Pahlman, B. Glimelius, and G. Lindmark
Prognostic Value of p53 Genetic Changes in Colorectal Cancer
J. Clin. Oncol., February 1, 1999; 17(2): 593 - 593.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
R. E. Felgar, K. R. Steward, J. B. Cousar, and W. R. Macon
T-Cell-Rich Large-B-Cell Lymphomas Contain Non-Activated CD8+ Cytolytic T Cells, Show Increased Tumor Cell Apoptosis, and Have Lower Bcl-2 Expression Than Diffuse Large-B-Cell Lymphomas
Am. J. Pathol., December 1, 1998; 153(6): 1707 - 1715.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. Nalca and V. M. Rangnekar
The G1-phase Growth-arresting Action of Interleukin-1 Is Independent of p53 and p21/WAF1 Function
J. Biol. Chem., November 13, 1998; 273(46): 30517 - 30523.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
C. Williams, T. Norberg, A. Ahmadian, F. Ponten, J. Bergh, M. Inganas, J. Lundeberg, and M. Uhlen
Assessment of sequence-based p53 gene analysis in human breast cancer: messenger RNA in comparison with genomic DNA targets
Clin. Chem., March 1, 1998; 44(3): 455 - 462.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
S. K. G. Grebe, B. McIver, I. D. Hay, P. S.-C. Wu, L. M. Z. Maciel, H. A. Drabkin, J. R. Goellner, C. S. Grant, R. B. Jenkins, and N. L. Eberhardt
Frequent Loss of Heterozygosity on Chromosomes 3p and 17p without VHL or p53 Mutations Suggests Involvement of Unidentified Tumor Suppressor Genes in Follicular Thyroid Carcinoma
J. Clin. Endocrinol. Metab., November 1, 1997; 82(11): 3684 - 3691.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.